Literature DB >> 26002288

miR-526a regulates apoptotic cell growth in human carcinoma cells.

Xiaoli Yang1, Cui Wang, Changzhi Xu, Zhifeng Yan, Congwen Wei, Kai Guan, Shengli Ma, Ye Cao, Liping Liu, Deyong Zou, Xiang He, Buchang Zhang, Qingjun Ma, Zirui Zheng.   

Abstract

MicroRNAs (miRNAs) play vital roles in the regulation of cell cycle, cell growth, apoptosis, and tumorigenesis. Our previous studies showed that miR-526a positively regulated innate immune response by suppressing CYLD expression, however, the functional relevance of miR-526a expression and cell growth remains to be evaluated. In this study, miR-526a overexpression was found to promote cancer cell proliferation, migration, and anchor-independent colony formation. The molecular mechanism(s) of miR-526a-mediated growth stimulation is associated with rapid cell cycle progression and inhibition of cell apoptosis by targeting CYLD. Taken together, these results provide evidence to show the stimulatory role of miR-526a in tumor migration and invasion through modulation of the canonical NF-κB signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26002288     DOI: 10.1007/s11010-015-2455-6

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer.

Authors:  S Zhong; C R Fields; N Su; Y-X Pan; K D Robertson
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

2.  Reduced expression of CYLD in human colon and hepatocellular carcinomas.

Authors:  Claus Hellerbrand; Elisabeth Bumes; Frauke Bataille; Wolfgang Dietmaier; Ramin Massoumi; Anja K Bosserhoff
Journal:  Carcinogenesis       Date:  2006-06-13       Impact factor: 4.944

Review 3.  A small piece in the cancer puzzle: microRNAs as tumor suppressors and oncogenes.

Authors:  O A Kent; J T Mendell
Journal:  Oncogene       Date:  2006-10-09       Impact factor: 9.867

4.  Reconstitution of the RIG-I pathway reveals a signaling role of unanchored polyubiquitin chains in innate immunity.

Authors:  Wenwen Zeng; Lijun Sun; Xiaomo Jiang; Xiang Chen; Fajian Hou; Anirban Adhikari; Ming Xu; Zhijian J Chen
Journal:  Cell       Date:  2010-04-16       Impact factor: 41.582

5.  The tumour suppressor CYLD negatively regulates NF-kappaB signalling by deubiquitination.

Authors:  Andrew Kovalenko; Christine Chable-Bessia; Giuseppina Cantarella; Alain Israël; David Wallach; Gilles Courtois
Journal:  Nature       Date:  2003-08-14       Impact factor: 49.962

Review 6.  Oncogenic ras-induced expression of cytokines: a new target of anti-cancer therapeutics.

Authors:  Brooke B Ancrile; Kevin M O'Hayer; Christopher M Counter
Journal:  Mol Interv       Date:  2008-02

7.  The tumour suppressor CYLD is a negative regulator of RIG-I-mediated antiviral response.

Authors:  Constantin S Friedman; Marie Anne O'Donnell; Diana Legarda-Addison; Aylwin Ng; Washington B Cárdenas; Jacob S Yount; Thomas M Moran; Christopher F Basler; Akihiko Komuro; Curt M Horvath; Ramnik Xavier; Adrian T Ting
Journal:  EMBO Rep       Date:  2008-07-18       Impact factor: 8.807

8.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma.

Authors:  Jonathan J Keats; Rafael Fonseca; Marta Chesi; Roelandt Schop; Angela Baker; Wee-Joo Chng; Scott Van Wier; Rodger Tiedemann; Chang-Xin Shi; Michael Sebag; Esteban Braggio; Travis Henry; Yuan-Xiao Zhu; Homer Fogle; Tammy Price-Troska; Gregory Ahmann; Catherine Mancini; Leslie A Brents; Shaji Kumar; Philip Greipp; Angela Dispenzieri; Barb Bryant; George Mulligan; Laurakay Bruhn; Michael Barrett; Riccardo Valdez; Jeff Trent; A Keith Stewart; John Carpten; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

9.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Authors:  Christina M Annunziata; R Eric Davis; Yulia Demchenko; William Bellamy; Ana Gabrea; Fenghuang Zhan; Georg Lenz; Ichiro Hanamura; George Wright; Wenming Xiao; Sandeep Dave; Elaine M Hurt; Bruce Tan; Hong Zhao; Owen Stephens; Madhumita Santra; David R Williams; Lenny Dang; Bart Barlogie; John D Shaughnessy; W Michael Kuehl; Louis M Staudt
Journal:  Cancer Cell       Date:  2007-08       Impact factor: 31.743

10.  Structural basis for the prion-like MAVS filaments in antiviral innate immunity.

Authors:  Hui Xu; Xiaojing He; Hui Zheng; Lily J Huang; Fajian Hou; Zhiheng Yu; Michael Jason de la Cruz; Brian Borkowski; Xuewu Zhang; Zhijian J Chen; Qiu-Xing Jiang
Journal:  Elife       Date:  2014-01-01       Impact factor: 8.140

View more
  3 in total

1.  Estimating survival time of patients with glioblastoma multiforme and characterization of the identified microRNA signatures.

Authors:  Srinivasulu Yerukala Sathipati; Hui-Ling Huang; Shinn-Ying Ho
Journal:  BMC Genomics       Date:  2016-12-22       Impact factor: 3.969

2.  miR-130b, an onco-miRNA in bladder cancer, is directly regulated by NF-κB and sustains NF-κB activation by decreasing Cylindromatosis expression.

Authors:  Xiaolu Cui; Chuize Kong; Yuyan Zhu; Yu Zeng; Zhe Zhang; Xiankui Liu; Bo Zhan; Chiyuan Piao; Zhenming Jiang
Journal:  Oncotarget       Date:  2016-07-26

3.  HNRNPA2/B1 is upregulated in endocrine-resistant LCC9 breast cancer cells and alters the miRNA transcriptome when overexpressed in MCF-7 cells.

Authors:  Carolyn M Klinge; Kellianne M Piell; Christine Schaner Tooley; Eric C Rouchka
Journal:  Sci Rep       Date:  2019-07-01       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.